Olema Oncology previews Phase III trial plans for dual-mechanism SERD in breast cancer

Olema Oncology previews Phase III trial plans for dual-mechanism SERD in breast cancer

Source: 
Clinical Trials Arena
snippet: 

After multiple high-profile clinical trial terminations for selective estrogen receptor degraders (SERDs) in breast cancer, Olema Oncology is taking a stab at the notoriously hard-to-treat disease with a new dual-mechanism approach.